Shin Poong Pharm.Co.Ltd. Total Liabilities
Shin Poong Pharm.Co.Ltd. total liabilities. Based on the latest financial reports, Shin Poong Pharm.Co.Ltd. (019170) has total liabilities worth ₩81.74 Billion KRW (≈ $55.39 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 019170 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shin Poong Pharm.Co.Ltd. (2003–2025)
Total liabilities of Shin Poong Pharm.Co.Ltd. from 2003 to 2025. This chart illustrates how Shin Poong Pharm.Co.Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Shin Poong Pharm.Co.Ltd. to see how much of total assets are deployed in long-term investments.
Shin Poong Pharm.Co.Ltd. Competitors by Total Liabilities
The table below lists competitors of Shin Poong Pharm.Co.Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Firm Capital Mortgage Invest Corp
TO:FC
|
Canada | CA$152.00 Million |
|
Kingsway Financial Services Inc
NYSE:KFS
|
USA | $199.31 Million |
|
Prataap Snacks Limited
NSE:DIAMONDYD
|
India | Rs2.21 Billion |
|
Bangkok Land Public Company Limited
BK:BLAND-R
|
Thailand | ฿12.48 Billion |
|
Galaxy Far East
TWO:6227
|
Taiwan | NT$7.47 Billion |
|
Element 29 Resources Inc
V:ECU
|
Canada | CA$1.25 Million |
|
SOLiD Inc
KQ:050890
|
Korea | ₩183.33 Billion |
|
Osung Advanced Materials Co. Ltd
KQ:052420
|
Korea | ₩102.26 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down Shin Poong Pharm.Co.Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 019170 asset base.
Liquidity & Leverage Metrics
Shin Poong Pharm.Co.Ltd. Total Liabilities Ratios Explained
Shin Poong Pharm.Co.Ltd. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shin Poong Pharm.Co.Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shin Poong Pharm.Co.Ltd. (2003–2025)
The table below shows the annual total liabilities of Shin Poong Pharm.Co.Ltd. from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩81.74 Billion ≈ $55.39 Million |
-2.70% |
| 2024-12-31 | ₩84.00 Billion ≈ $56.93 Million |
+5.93% |
| 2023-12-31 | ₩79.30 Billion ≈ $53.74 Million |
+157.66% |
| 2022-12-31 | ₩30.78 Billion ≈ $20.86 Million |
-19.06% |
| 2021-12-31 | ₩38.03 Billion ≈ $25.77 Million |
-66.30% |
| 2020-12-31 | ₩112.82 Billion ≈ $76.46 Million |
-34.02% |
| 2019-12-31 | ₩170.99 Billion ≈ $115.87 Million |
-1.43% |
| 2018-12-31 | ₩173.47 Billion ≈ $117.56 Million |
-1.16% |
| 2017-12-31 | ₩175.50 Billion ≈ $118.93 Million |
-12.09% |
| 2016-12-31 | ₩199.64 Billion ≈ $135.29 Million |
-7.52% |
| 2015-12-31 | ₩215.87 Billion ≈ $146.29 Million |
-0.88% |
| 2014-12-31 | ₩217.78 Billion ≈ $147.59 Million |
+4.92% |
| 2013-12-31 | ₩207.57 Billion ≈ $140.67 Million |
+8.70% |
| 2012-12-31 | ₩190.95 Billion ≈ $129.41 Million |
-3.87% |
| 2011-12-31 | ₩198.64 Billion ≈ $134.61 Million |
+16.48% |
| 2010-12-31 | ₩170.54 Billion ≈ $115.57 Million |
+3.46% |
| 2009-12-31 | ₩164.84 Billion ≈ $111.71 Million |
+17.18% |
| 2008-12-31 | ₩140.67 Billion ≈ $95.33 Million |
+36.11% |
| 2007-12-31 | ₩103.35 Billion ≈ $70.04 Million |
+9.03% |
| 2006-12-31 | ₩94.79 Billion ≈ $64.24 Million |
+2.57% |
| 2005-12-31 | ₩92.42 Billion ≈ $62.63 Million |
+5.73% |
| 2004-12-31 | ₩87.42 Billion ≈ $59.24 Million |
+12.65% |
| 2003-12-31 | ₩77.60 Billion ≈ $52.59 Million |
-- |
About Shin Poong Pharm.Co.Ltd.
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more